Shandong Buchang Pharmaceuticals (603858.SH) has announced a forecasted pre-loss, with an estimated net loss of 428 million to 808 million yuan in 2024.

Shandong Buchang Pharmaceuticals (603858.SH) announced that it is expected to incur a net loss attributable to shareholders of the company in the amount of approximately 428 million to 808 million yuan in the fiscal year 2024. This represents a loss compared to the same period of the previous year. Some products have experienced decreased sales due to restrictions on medical insurance or being included in a key monitoring list by certain provinces, resulting in a decrease in revenue for the year. This has led to a change in the product revenue structure and an overall decrease in gross profit margin.